Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Kraken Zone Discovery Unlocks Significant Value (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Intellia Therapeutics Inc NTLA

Healthcare Biotechnology
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:NTLA)

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026

GlobeNewswire 1 day ago

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

GlobeNewswire 2 days ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

GlobeNewswire 6 days ago

Intellia Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire 8 days ago

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

GlobeNewswire 13 days ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 6, 2026

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN

GlobeNewswire January 27, 2026

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 7, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 2, 2026
View More News ››

Opinion & Analysis (NDAQ:NTLA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:NTLA)

Sell buddy sell.

Otherwise you guys out there will be losing your money with this stock today anyway
coolfooldumbguy - October 27, 2025

Using technical analysis for this stock.

Buy buddy buy because it's going up big-time today,so good luck to all of you guys
coolfooldumbguy - September 18, 2025

Intellia Therapeutics, Inc. (NASDAQ:NTLA): Pioneering the Ne

http://beyondspx.com/2024/08/01/intellia-therapeutics-inc-nasdaqntla-pioneering-the-next-generation-of-gene-editing-therapies/
MikeTester - August 2, 2024

REVERSAL TIME

If youre a day trader, you should definitely check out BULLALERTS They send a watchlist covering the top pre-market movers every day...
lebaoxuiyo15 - November 1, 2022

🎥📰Anthony Durkacz on Building a Turnaround at FSD Pharma📣

<< View Post To Watch Video >>
HarryPerkins - November 18, 2021

🎉📣FSD Pharma's Research and Clinical Advisory Board📢

Dr. Eleanor N. Fish, a world-renowned immunologist and cytokine expert, has been appointed to FSD Pharma's Research and Clinical...
HarryPerkins - November 17, 2021
View more Bullboard ››

Eshbal Functional Food Inc

Eshbal Functional Food Inc

Eshbal Functional Food Inc. researches, develops, and manufactures food products and dietary supplements Israel, North ...
View More »

Podcasts